Alex S F Doney: Influence Statistics

Alex S F Doney

Alex S F Doney

MEMO Research, University of Dundee, Dundee, UK | Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK | Population Health and ...

Alex S F Doney: Expert Impact

Concepts for which Alex S F Doney has direct influence: Type 2 diabetes , 2 diabetes , Type 2 , Blood pressure , Heart failure , Heart rate , Statin treatment .

Alex S F Doney: KOL impact

Concepts related to the work of other authors for which for which Alex S F Doney has influence: Type 2 diabetes , Genetic variants , Insulin resistance , Mendelian randomization , Cardiovascular disease , Metabolic syndrome , Blood pressure .

KOL Resume for Alex S F Doney

Year
2022

MEMO Research, University of Dundee, Dundee, UK

Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, U.K.

2020

Division of Molecular & Clinical Medicine (A.S.F.D.), School of Medicine, University of Dundee.

2019

Division of Population Health and Genomics, Ninewells Hospital & Medical School, University of Dundee, Dundee, Scotland, U.K

2018

Medicine Monitoring Unit (MEMO), School of Medicine, University of Dundee. Ninewells Hospital, Dundee, UK

2017

Medicines Monitoring Unit (MEMO) and Hypertension Research Centre (HRC)

Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD19SY, Scotland, UK

2016

Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, Ninewells Hospital and Medical School, Dundee, UK.

Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK

2015

Diabetes Research Centre, Biomedical Research Institute, University of Dundee, Ninewells Hospital, Dundee, UK.

Department of Pharmacogenetics & Pharmacogenomics, Ninewells Hospital & Medical School, University of Dundee, Dundee, UK

2014

Medical Research Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK

2013

Medical Research Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee

2012

Medical Research Institute, University of Dundee, Dundee, UK.

Clinical Research Centre, University of Dundee-Wellcome Trust Centre for Molecular Medicine, Level 7, Ninewells Hospital, Dundee DD1 9SY, Scotland,

2011

Department of Medicine and Therapeutics, Population Pharmacogenetics Group, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom;

2010

Diabetes Research Centre, Biomedical Research Institute, University of Dundee, Ninewells Hospital, Dundee, UK

Biomedical Research Centre, Ninewells Hospital and Medical School, Dundee, U.K.;

Division of Medical Sciences, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom

2009

Ninewells Hospital and Medical School, Dundee, U.K.;

From the Diabetes Research Group (A.S.F.D., E.P., A.D.M.) and the Population Pharmacogenetics Group (J.D., C.H.K., L.A.D., C.N.A.P.), Biomedical Research Institute, University of Dundee, Dundee, United Kingdom.

Tayside Centre for General Practice, Division of Clinical & Population Sciences and Education, University of Dundee, Dundee, UK;

2008

Health Informatics Centre, University of Dundee, Scotland

Diabetes Research Centre, Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee, U.K

Ninewells Hospital and Medical School, Dundee, UK

2007

Diabetes Research Group, Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK.

2006

Division of Medicine and Therapeutics, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom

2005

From the Institute for Cardiovascular Research, Biomedical Research Centre (S.L., C.N.A.P.), and Department of Medicine and Therapeutics (A.S.F.D., G.P.L., A.D.M.), Ninewells Hospital and Medical School, Dundee, Scotland.

The Institute of Cardiovascular Research, Ninewells Hospital and Medical School, Dundee, DD1 9SY, Scotland, UK

2004

From the Institute for Cardiovascular Research (B.F., C.N.A.P.), Biomedical Research Centre, and the Department of Medicine and Therapeutics (A.S.F.D., G.L., A.D.M.), Ninewells Hospital and Medical School, Dundee, Scotland.

2003

Department of Clinical Pharmacology, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, Scotland, United Kingdom

Ninewells Hospital and Medical School, Dundee, Scotland, UK

2002

Medicines Monitoring Unit, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY. Scotland, United Kingdom

Prominent publications by Alex S F Doney

KOL-Index: 12670 . BACKGROUND: The discovery of low-frequency coding variants affecting the risk of coronary artery disease has facilitated the identification of therapeutic targets. METHODS: Through DNA genotyping, we tested 54,003 coding-sequence variants covering 13,715 human genes in up to 72,868 patients with coronary artery disease and 120,770 controls who did not have coronary artery disease. Through ...
Known for Coronary Disease | Function Angptl4 | Coding Variation | Triglyceride Levels
KOL-Index: 10785 . To identify common variants influencing body mass index (BMI), we analyzed genome-wide association data from 16,876 individuals of European descent. After previously reported variants in FTO, the strongest association signal (rs17782313, P = 2.9 × 10−6) mapped 188 kb downstream of MC4R (melanocortin-4 receptor), mutations of which are the leading cause of monogenic severe childhood-onset ...
Known for Common Variants | Fat Mass | Topic Receptor | Mc4r Melanocortin
KOL-Index: 10397 . BACKGROUND: Glutathione S-transferases (GSTs) modulate oxidative stress, and variation in GST genes has been associated with cardiovascular disease risk. We prospectively determined smoking-related cardiovascular morbidity by GST genotype in a large cohort of individuals with type 2 diabetes using a population-based diabetes research database (DARTS). METHODS AND RESULTS: We performed a ...
Known for Type 2 Diabetes | Cardiovascular Morbidity | 2 Diabetic | Gstt1 Gene
KOL-Index: 10133 . Metformin is the most commonly used pharmacological therapy for type 2 diabetes. We report a genome-wide association study for glycemic response to metformin in 1,024 Scottish individuals with type 2 diabetes with replication in two cohorts including 1,783 Scottish individuals and 1,113 individuals from the UK Prospective Diabetes Study. In a combined meta-analysis, we identified a SNP, ...
Known for Glycemic Response | 2 Diabetes | Common Variants | Atm Ataxia Telangiectasia
KOL-Index: 9900 . OBJECTIVE: Metformin is actively transported into the liver by the organic cation transporter (OCT)1 (encoded by SLC22A1). In 12 normoglycemic individuals, reduced-function variants in SLC22A1 were shown to decrease the ability of metformin to reduce glucose excursion in response to oral glucose. We assessed the effect of two common loss-of-function polymorphisms in SLC22A1 on metformin ...
Known for Organic Cation Transporter | Glycemic Response | Godarts Study | Metformin Patients
KOL-Index: 9521 . Purpose: Semiautomated software applications derive quantitative retinal vascular parameters from fundus camera images. However, the extent of agreement between measurements from different applications is unclear. We evaluate the agreement between retinal measures from two software applications, the Singapore "I" Vessel Assessment (SIVA) and the Vessel Assessment and Measurement Platform ...
Known for Vampire Measurements | Retinal Vascular | Vessel Assessment | Cohort 1936
KOL-Index: 9358 . To identify genetic loci influencing central obesity and fat distribution, we performed a meta-analysis of 16 genome-wide association studies (GWAS, N = 38,580) informative for adult waist circumference (WC) and waist-hip ratio (WHR). We selected 26 SNPs for follow-up, for which the evidence of association with measures of central adiposity (WC and/or WHR) was strong and disproportionate ...
Known for Fat Distribution | Central Adiposity | Wc Whr | Waist Circumference
KOL-Index: 8970 . Triglycerides are transported in plasma by specific triglyceride-rich lipoproteins; in epidemiological studies, increased triglyceride levels correlate with higher risk for coronary artery disease (CAD). However, it is unclear whether this association reflects causal processes. We used 185 common variants recently mapped for plasma lipids (P < 5 × 10(-8) for each) to examine the role of ...
Known for Plasma Triglycerides | Common Variants | Artery Disease | Cad Risk
KOL-Index: 8950 . OBJECTIVE: There is considerable interindividual variation in sulfonylurea response in type 2 diabetes. Transcription factor 7-like 2 (TCF7L2) variants have been identified to be strongly associated with type 2 diabetes risk, probably due to decreased beta-cell function. We hypothesized that variation in TCF7L2 would influence response to sulfonylureas but not metformin. We studied the ...
Known for Tcf7l2 Genotype | Response Sulfonylureas | 2 Diabetes | Treatment Failure
KOL-Index: 8939 . OBJECTIVES: The LPA single-nucleotide polymorphism rs10455872 has been associated with low-density lipoprotein cholesterol (LDLc) lowering response to statins in several randomized control trials (RCTs) and is a known coronary artery disease (CAD) marker. However, it is unclear what residual risk of CAD this marker may have during statin treatment. METHODS: Using electronic medical records ...
Known for Statin Treatment | Lipoprotein Cholesterol | Coronary Artery | Ldlc Response
KOL-Index: 8845 . BACKGROUND: Genome-wide association studies have so far identified 56 loci associated with risk of coronary artery disease (CAD). Many CAD loci show pleiotropy; that is, they are also associated with other diseases or traits. OBJECTIVES: This study sought to systematically test if genetic variants identified for non-CAD diseases/traits also associate with CAD and to undertake a ...
Known for Artery Disease | Cad Loci | Genome Wide | Genetic Pleiotropy
KOL-Index: 8602 . We performed fine mapping of 39 established type 2 diabetes (T2D) loci in 27,206 cases and 57,574 controls of European ancestry. We identified 49 distinct association signals at these loci, including five mapping in or near KCNQ1. 'Credible sets' of the variants most likely to drive each distinct signal mapped predominantly to noncoding sequence, implying that association with T2D is ...
Known for Causal Mechanisms | Genetic Fine | 2 Diabetes | Single Nucleotide Receptor
KOL-Index: 8304 . BACKGROUND: Apolipoprotein E (APOE) genotypes have been associated with variations in plasma-lipid levels and with response to statins, although the influence of APOE on the response to statins remains controversial, especially in patients with diabetes. We sought to evaluate the association of the APOE genotype with the low-density lipoprotein cholesterol (LDLc)-lowering response to ...
Known for Statin Treatment | Apoe Genotype | Fatty Acids | Studies Diabetes
KOL-Index: 8293 . To further understanding of the genetic basis of type 2 diabetes (T2D) susceptibility, we aggregated published meta-analyses of genome-wide association studies (GWAS), including 26,488 cases and 83,964 controls of European, east Asian, south Asian and Mexican and Mexican American ancestry. We observed a significant excess in the directional consistency of T2D risk alleles across ancestry ...
Known for Diabetes Susceptibility | Ancestry Meta | Type 2 | Genetic Architecture
KOL-Index: 8175 . BACKGROUND: Considerable interindividual variation exists in cholesterol-lowering response to 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) inhibitors (statins). HMGCR catalyzes the rate-limiting step in cholesterol biosynthesis, and also plays a significant role in cholesterol homeostasis. We evaluated the association of a single nucleotide polymorphism (rs17238540) in the HMGCR ...
Known for Statin Treatment | Coa Reductase | Lowering Response | Total Cholesterol

Key People For Type 2 Diabetes

Top KOLs in the world
#1
David Richard Matthews
type 2 diabetes sri lanka growth hormone
#2
Frank B Hu
type 2 diabetes cardiovascular disease physical activity
#3
Rury R Holman
type 2 diabetes cardiovascular disease impaired glucose tolerance
#4
David Matthew Nathan
type 2 diabetes insulin resistance cardiovascular disease
#5
John B Buse
type 2 diabetes insulin degludec cardiovascular outcomes
#6
Tuomilehto Tuomilehto
type 2 diabetes blood pressure north karelia

MEMO Research, University of Dundee, Dundee, UK | Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK | Population Health and Genomics, University of Dundee, Dundee, UK | NIHR Global Health Research Unit o